HER2/neu is an oncogenic tumor-associated antigen over-expressed in several human tumors including breast and ovarian cancer. The selective expression of HER2/neu and its role in epithelial carcinogenesis makes HER2/neu an ideal target for immunotherapy. Tumor-derived chaperone-rich cell lysate (CRCL), containing numerous heat shock proteins, has successfully been used to generate tumor-specific immunity against a wide range of murine tumors and is a great candidate for an effective vaccine against HER2/neu positive tumors. In the first part of this study, the potency of human ovarian cancer-derived CRCL to activate dendritic cells (DCs) and to generate tumor-specific T cells in vitro has been investigated. Chaperone-rich cell lysate was generated from primary ovarian cancer tissues and SKOV3-A2, a HER2/neu, Wilm's tumor gene 1 (WT1) and HLA-A2 positive human ovarian tumor cell line. T cells from healthy donors and from ovarian cancer patients secreted higher amounts of interferon-γ following in vitro re-stimulation with ovarian cancer-derived CRCL compared to HER2/neu or WT1 peptide-pulsed DCs. We were also able to generate cytotoxic T lymphocyte activity against cancer-specific antigens such as HER2/neu and WT1 from all healthy donors, but from only one of the four ovarian cancer patients with bulky disease. In the second part of the study, the potency of tumor-derived CRCL to elicit the humoral immune response against a murine HER2/neu positive tumor (TUBO) has been examined. Vaccination of mice bearing a palpable tumor efficiently delayed the development of the tumor. In the vaccinated mice, CRCL vaccination induced significant anti-HER2/neu antibodies. Using B cell deficient mice and antibody transfer experiments, we have shown that the induction of anti-HER2/neu antibodies is both necessary and sufficient for the anti-tumor effect. Further, we have demonstrated that serum from TUB0 CRCL-vaccinated mice stimulated the internalization of the HER2/neu molecules, resulting in the down-regulation of their surface expression. Moreover, antibody-dependent cellular cytotoxicity has been observed against TUBO cells when presented with sera from vaccinated mice. These results indicate that CRCL may be a potent adjuvant for women suffering from HER2/neu positive ovarian or breast cancer and that this personalized vaccine may be a promising approach for active immunotherapy.
| Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/193817 |
| Date | January 2007 |
| Creators | Li, Gang |
| Contributors | Katsanis, Emmanuel, Akporiaye, Emmanuel T., Schluter, Samuel F., Cranmer, Lee D. |
| Publisher | The University of Arizona. |
| Source Sets | University of Arizona |
| Language | English |
| Detected Language | English |
| Type | text, Electronic Dissertation |
| Rights | Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. |
Page generated in 0.0021 seconds